spacer
home > ict > spring 2006 > india – the new tiger of clinical trials
PUBLICATIONS
International Clinical Trials

India – The New Tiger of Clinical Trials

As India becomes an ideal destination for clinical trials, success depends upon effective multilingual, cross-cultural communications, reports Gary Muddyman of Conversis

In the on-going race to develop the next billion dollar home-run medication, pharmaceutical companies are investing more time and financial resources than ever on R&D. In an effort to control costs and increase their return on investment, many are looking to the developing world to conduct clinical trials.

Expanding any business into new international markets is difficult. Add the many regulatory and legal issues associated with conducting clinical trials overseas and companies will face even more challenges. More and more pharmaceutical companies are taking advantage of the services provided by globalisation, internationalisation, localisation and translation (GILT) vendors.

Given the technically challenging nature of GILT services, it is critical that pharmaceutical companies choose the right partner and undertake a detailed cross-borders strategy. Only with the right translation and cross-cultural services in place can a pharmaceutical firm establish the trust needed to conduct a successful clinical trial in foreign markets. With improved economic landscapes and communication infrastructures, including localisation and translation services, many countries once thought to be ‘third world’ are now centres for excellence in international clinical trials.

Nowhere is this truer than in India. Today, India is the world’s largest democracy and is second only to China in terms of population, which it is expected to surpass within the next 50 years. Often referred to as the new ‘tiger’ of economics, India boasts the world’s fourth largest economy in terms of GDP. With a cultural heritage that goes back more than 5,000 years, it is also one of the world’s oldest civilizations, giving it much of its cultural richness. Despite a significant population that is still living in poverty, India has recently seen a period of dramatic economic growth, including a number of multinational companies outsourcing their clinical trials to India. With a population in excess of one billion, India offers multinational pharmaceutical companies an ideal destination for their clinical trials.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Gary Muddyman is Managing Director and CEO of Conversis, a leading UK-based provider of globalisation, internationalisation, localisation and translation (GILT) services. Gary founded Conversis, and leads the company’s strategic business development. Prior to joining Conversis, he served as Director of Operations for K International Plc. Previously, Gary spent 16 years working for London-based HSBC Asset Finance UK Ltd, in particular helping to create the Metropolitan Collection Services, the debt management arm of HSBC. Gary received his master’s degree in Business Administration from Warwick University.
spacer
Gary Muddyman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Applikon Biotechnology launches fully customizable single-use bioreactor using 3D printing technology

Dutch-based upstream bioprocess equipment specialist Applikon Biotechnology B.V. (Applikon) has launched the single-use AppliFlex ST lab-scale bioreactor as a significant extension to its range of innovative bioreactor systems. AppliFlex ST is a fully customizable and scalable stirred tank single-use bioreactor that uses 3D printing technology to provide a head plate that is uniquely configured to each individual process, including custom impeller design, and different sample port connections.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement